Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
Clinical trial NCT05382312 · COMPLETED
Trial details
- NCT number
- NCT05382312
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-26
- Primary completion
- 2025-05-27
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.